Alphapharm Pty Ltd — Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tablets
What are the defects?
Potential for broken and/or split tablets.
In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety.
What are the hazards?
A broken or split tablet may lead to ineffective dosing, which may increase the risk of adverse health effects.
What should consumers do?
Consumers that have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 should consult their treating physician for advice.
Consumers that have any unexpired product should return the product to their pharmacist for a refund.
A TGA web statement can be found at https://www.tga.gov.au/alert/tenofovir-disoproxil-emtricitabine-mylan-30...
For further information, please contact Alphapharm on 1800 274 276.
Chemists and Pharmacies
Recall advertisements and supporting documentation
Therapeutic Goods Administration is the responsible regulator for this recall.